Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
May 01, 2024 08:00 ET
|
Peak Bio, Inc.
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in...
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
March 05, 2024 08:00 ET
|
Peak Bio, Inc.
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and...
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
January 04, 2024 08:00 ET
|
Peak Bio, Inc.
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin...
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing
September 19, 2023 16:00 ET
|
Peak Bio, Inc.
Pleasanton, CA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and...
Peak Bio, Inc. Announces Up-listing to OTCQB Market
August 31, 2023 09:35 ET
|
Peak Bio, Inc.
Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing...
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
August 31, 2023 08:00 ET
|
Peak Bio, Inc.
Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation...
Peak Bio, Inc. Announces its Application to Uplist to the OTCQB Venture Market
August 29, 2023 08:00 ET
|
Peak Bio, Inc.
Pleasanton, CA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing...
Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital
August 24, 2023 16:05 ET
|
Peak Bio, Inc.
Pleasanton, CA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing...
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting
August 23, 2023 15:50 ET
|
Peak Bio, Inc.
Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation...